# Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet

> **NCT01376193** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 500 (actual)

## Conditions studied

- Migraine Disorders

## Interventions

- **DRUG:** Naratriptan

## Key facts

- **NCT ID:** NCT01376193
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2013-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01376193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01376193, "Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01376193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*